Article Details

Morgan Stanley Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

Retrieved on: 2021-04-19 18:45:00

Tags for this article:

Click the tags to see associated articles and topics

Morgan Stanley Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN). View article details on hiswai:

Excerpt

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on BioMarin Pharmaceutical (BMRN) today and set a price target of $82.00.

Article found on: www.smarteranalyst.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up